When a doctor orders a scan, the patient can go to a hospital or a standalone centre. RadNet runs the largest US chain of such centres.
The company · 2 · What exactly does it sell?
Private insurers pay over half
Each $1 of sales, 2025
55%26%12%6%
Private insurersMedicare and MedicaidOther payers and feesFixed fees per member
Some health plans pay a fixed fee per member instead of per scan.
The company · 3 · How does it make money?
Paid per scan, mostly by insurers
$2.38Brevenue in the past year
3.1%operating profit per $1
+47%more shares since 2021
Growth has come partly through new shares, so each share owns less of the business.
Is it a good business? · 4 · What gives it an edge?
Cheaper scans and dense networks of centres
About $106 vs $30
hospital against office pay for one scan
442
centres in a few dense regions
9.6%
scan growth at existing centres
Scans grow faster at its centres than across the country, so it is taking work from hospitals.
Is it a good business? · 5 · What is the catch?
Hospitals, private chains and AI makers
HCAhospitals can open their own centres
SimonMedmore than 170 locations, private
Over 1,200radiology AI products cleared by the FDA
Listed rivals: HCA · GEHC · 328130.KQ
Hospitals still do most scans, and AI software is crowded.
Is it a good business? · 6 · What does its record show?
Revenue grew while profit per dollar halved
Sales, $B
1.3
1.4
1.6
1.8
2.0
2.4
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$1.32B → $2.38Brevenue, 2021 to the past year
Profit6.3% → 3.1%operating profit per $1
Shares+47%more shares since 2021
Pay in shares doubled and spending on equipment took most of operating cash.
Is it a good business? · 7 · How much room is there to grow?
The room is in taking hospital scans
About 93 millionUS CT scans in 2023
About 1.2 milliondone by RadNet
Near 1.3%its share of them
CT use grows slowly, and nobody counts MRI or PET scans by where they are done.
Is it a good business? · 8 · Who is in charge?
The founder has run it since 1992
1992Howard Berger took charge
Under 1%of the shares he owns
176,604shares insiders sold since November 2025, none bought
Pay rewards staying more than results: bonuses are at the board's discretion and long-term awards vest with time.
The story right now · 9 · Why do scans move to centres?
Insurers pay far less at a centre
About $106hospital pay for one scan
About $30office pay for the same scan
9.6%scan growth at its centres
Insurers and Medicare pay hospitals much more for the same scan. So they push patients to cheaper standalone centres like RadNet's.
The story right now · 10 · Why hasn't growth lifted profit?
Costs grew as fast as scans
More scansRevenue up 80%.
More equipment and payMost of the cash.
New shares for deals+47% since 2021.
AI may helpNot yet shown.
Analysts expect earnings per share to nearly double in 2027; the filings show a loss after pay in shares and deal costs.
The story right now · 11 · What changed lately?
Its biggest quarter, with a thin profit gain
$638.3Mrevenue, up 22.1%
16.5%cash profit per $1, from 16.2%
$350Mcash for ONRAD, plus 5M shares
8.9%growth in advanced scans at older centres
Solid quarter
The profit RadNet claims for ONRAD is unaudited, and Medicare's 2027 rules are pending.
The story right now · 12 · What is everyone arguing about?
An imaging leader with AI, or flat profit?
Many investors think
A growing imaging leader with AI on top
We think
Profit per dollar flat, and new shares shrink owners' slices
A Medicare cut to hospital pay would help it.
The price and our view · 13 · What is a share worth?
The price sits far above our best case
$6.52what we think a share is worth · the last close is of that
$6.52our value
Attractive below $5.22
Neutral
Unattractive above $7.82
$0.66gloomy: growth halves, less kept per $1
$6.52our estimate: experts' path, then slowing
$10.50sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · What if it all works?
As a bet on its AI software, it is fragile
Priced for successthe kind of bet this is
0.8×if it works
63%kept if it fails
Multiples of the company's value when the bet was last struck, 9 Oct 2026.
The price already pays for the AI software working, and about three-fifths is kept if it fails.
The price and our view · 15 · How could we be wrong?
AI and Medicare could swing either way
AI could lift profitBiggest
Would prove us wrong.
Medicare pays lessWatch
2027 rules.
New shares for dealsShowing now
5M for ONRAD.
ONRAD's profitUnknown
Unaudited.
Hospitals can open their own centres, and AI software is crowded.
The price and our view · 16 · How will we know?
March tests profit and the new purchase
Profit per $1 risesGood sign
Medicare cuts hospital payGood sign
Medicare cuts centre payBad sign
MAR 20272
Fourth-quarter 2026 results and the ONRAD closing, by 2 March. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 17 · So, what do we think?
The scan chain insurers prefer, priced as if it never slows
$6.52our value
Attractive below $5.22
Neutral
Unattractive above $7.82
UnattractiveHigh conviction
RadNet runs the largest US chain of imaging centres, paid far less than hospitals per scan, so patients keep coming. But growth has not lifted profit per dollar, Medicare may pay less and AI's gain is unproven.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
When a doctor orders an MRI, a CT scan or a mammogram, the patient can usually go to a hospital or to a standalone centre. RadNet runs 442 of those centres, clustered in California, New York, New Jersey, Maryland and a few other states, and says it is the largest such chain in the country.
MRI and CT are most of the money: MRI alone brought 37.7% of its imaging payments in 2025. Its contracted radiologists read the images, and the report goes back to the doctor.
How it makes money
RadNet is paid per scan, mostly by private insurers ($1.13B of 2025's $2.04B revenue) and Medicare ($477M). Some health plans instead pay a fixed monthly fee per member, whatever the number of scans.
A complex scan pays much more than an X-ray, so growth in MRI, CT and PET is what lifts revenue. A small software arm also sells imaging and AI programs to hospitals.
Growth and profit
What growth costs
Growth has not made RadNet more profitable. Revenue rose by more than half from 2021 to 2025 while operating profit fell, pay in shares doubled, and capital spending on centres and scanners now takes most of the cash the business brings in.
Its record
The numbers
Is it growing?Steady
Sales grew 21% over the twelve months to Sep 2026, faster than the 12% in the year to Dec 2025.
Is it profitable?Thin
Operating margin is 3.1%, down from 6.1% in the year to Dec 2023.
How steady is it?Steady
Yearly sales growth has ranged from +8.7% to +23% over the last 5 years.
Does it earn good returns?Low
Each dollar put into the business earns 1.9% a year after tax, down from 6.9% in the year to Dec 2021.
Is it making cash?Thin
It turned 4.8% of sales into free cash, $115M over the last twelve months.
Is the balance sheet safe?Light debt
It owes $575M more than the cash it holds, about 1.7 years of the cash its operations bring in.
Are shares being diluted?Diluting
The share count rose 48% in 4.8 years, and pay in shares costs 2.5% of sales.
Why it wins
The evidence
The edge is price and density. Medicare's own figures show a hospital department paid about $106 for a bone-density scan an office does for about $30, so insurers prefer the cheaper centre, and RadNet has the most centres where it operates.
The evidence it works: scans at its existing centres grew 9.6% in Q2 2026, while CT use across the country is growing only slowly. That gap means it is taking work from hospitals.
Who could beat it
The rivals in full
Hospitals still do most scans and can open centres of their own; HCA lists imaging centres among its rivals. Private chains such as SimonMed, with more than 170 locations, chase the same patients. In software, the FDA has cleared over 1,200 radiology AI products, so RadNet's AI arm sells into a crowded field.
Each rival
SimonMedprivate
Runs over 170 outpatient imaging centres in western states, selling AI-enhanced scans at low prices to the same referrers and payers.
Hospital outpatient departments, such as HCA'sHCA
Do the same scans in their own outpatient departments and freestanding centres, keeping the patient inside the health system.
Other private-equity-backed imaging chainsprivate
Regional chains backed by buyout funds buy centres in RadNet's markets and bid for the same payer contracts and acquisitions.
GE HealthCare and LunitGEHC328130.KQ
Sell imaging AI and reading software to hospitals and centres, the products Digital Health sells outside RadNet.
Aidoc and Therapixelprivate
Private AI firms with FDA-cleared triage and mammography software sold to the same radiology buyers.
How big it could get
The market and who has signed
The market
Americans had about 93 million CT scans in 2023, and RadNet did about 1.2 million of them, near 1.3%. CT use is growing slowly, so the room is in taking scans from hospitals rather than in the market growing.
Nobody this search could read counts MRI or PET scans by where they are done, so the full market cannot be sized from outside.
Who has signed
Most revenue is scan by scan, with nothing signed in advance. The firmer parts: 157 centres run as joint ventures with hospital systems, health plans paying fixed fees worth $125.5M in 2025, and about $37M of software contracts signed in the first half of 2026.
Who runs it
Leaders, pay and the cash
Who runs it
Howard Berger, 81, has run RadNet since 1992 and built it by buying chains and partnering with hospitals. He owns under 1% of the shares, and all directors and officers together about 5%. Doctors' groups owned by senior managers staff centres in six states.
Pay rewards staying more than results: 2025 bonuses were set at the board's discretion and long-term awards are shares that vest with time. Insiders have sold, not bought, this year.
What they did with the money
Management spends the cash on new centres, scanners and acquisitions. In the first half of 2026 it paid $315.7M for businesses, including a French AI firm, and borrowed $248.9M more. Earlier deals were paid with new shares, which is why each share owns less of the company than in 2021.
The last report
The latest report
RadNet's Q3 2026 revenue rose 22% and it raised its forecast a third time
What it did to the thesis Solid quarter
It confirmed the growth half of the argument again: patients keep coming and the forecast rose. The margin gain was too small to answer the half the price needs, so whether growth ever makes the business more profitable stays open.
The report
The September 2026 quarter was RadNet's biggest yet. Revenue rose 22.1% to $638.3M and earnings before interest, tax and depreciation, its main measure, 23.8% to $105.0M. Management raised its yearly forecast for the third time.
The margin moved only a little: 16.5% of each revenue dollar, against 16.2% a year earlier. Advanced scans at centres open a year rose 8.9%, a touch under the pace we watch. Management said a raised forecast just adds the quarter's beat.
Final Medicare rates cost about $5M of 2027 revenue, and management said the final hospital rule pays hospitals less for some scans.
What's happening now
The background
The shares have swung hard: from near $80 last November to $50.82 in June and to $76.00 after three raised forecasts.
The September-quarter results beat the quarter the last forecast implied; the fourth quarter and the ONRAD closing are the next tests, and Medicare's final 2027 rules follow. On 26 October RadNet agreed to buy teleradiology firm ONRAD for $350M in cash and 5M shares; the profit it claims for it is unchecked.
Where we disagree
Both sides in full
The market
A growing outpatient imaging leader with AI on top; nine of 11 analysts rate it a buy.
We believe
The patients are real, but margins have not moved in years and growth reaches shareholders diluted.
The argument
Analysts expect earnings per share to nearly double in 2027. The filings show a loss over the past year after pay in shares and deal costs, margins flat near 16%, and 47% more shares since 2021.
Against us: growth is real and broad, the forecast has been raised twice this year, and a Medicare rule cutting hospital pay would send more patients its way.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
The three cases
Bear case$0.66
Growth runs at half the analysts' path, 8% and 5%, the margin settles a fifth lower at 2.6%, and new capital earns only the 8% rate: the downturn test.
Our value$6.52
Revenue grows 15% and 10% over three years, the analysts' path (C43) measured from the twelve months to September, then fades toward 4%, closing 30% of the gap each year; the margin moves to 3.2%, the analysts' year-three figure after stock pay.
Bull case$10.50
Growth runs a quarter above the analysts' path, 19% and 12%, the margin reaches 3.5%, and new capital earns 15%.
The bet
Seen as a bet
The bet is on Digital Health, the software and AI that read scans. It loses money and most of its recent growth was bought, so the imaging centres are counted separately, at the price this thesis would call fair.
If the software keeps growing about a fifth a year, the shares end up worth less than today, because the price already pays far more for it than that is worth. If it never earns, shareholders keep the centres, about three-fifths of today's value.
What could go wrong
Every risk
The risks
AI could lift margins
If AI drafts half of reports by mid-2027, as management plans, reading costs could fall and margins rise, which would make us wrong.
Medicare could pay less
Medicare is about a quarter of revenue; management says the proposed 2027 rule costs under $1M, but the final rule is not out.
Hospitals could compete harder
If hospitals cut prices or keep their higher rates, the flow of patients to cheaper centres could slow.
A founder of 81
Berger has run the company since 1992 and his doctors' groups staff many centres; no successor is named.
Salaries keep rising
Technologists and radiologists are scarce, and pay rose 6.8% at existing centres in Q2 2026.
What we still do not know
What share of US scans is done outside hospitals, and how fast is it rising?
How much does RadNet earn per scan against a hospital, insurer by insurer?
How much of the software arm's revenue would stay if RadNet stopped buying from it?
Does ONRAD earn the profit RadNet says, and how is the cash price paid for?
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $7.82, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $5.22, 80% of what we think the business is worth.
→ Neutral
The imaging centres keep 17.5 cents of each revenue dollar as those earnings for a full year. Scans of MRI, CT and PET at existing centres keep growing at least 8% a year.
The next test
It supports the case if
Imaging adjusted EBITDA under $89M in the fourth quarter, or a full-year imaging margin below 17%, with growth kept only by acquisitions.
It pressures the case if
Imaging adjusted EBITDA above $102M in the fourth quarter with a full-year margin over 17%, and same-centre advanced scans up 9% or more.
We would also be wrong if
Cash after acquisitions pays for growth without new shares for two years.
Medicare makes hospitals take the office price for simple scans from 2027.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
3 of 4
Execution record
3 of 4
Per share capture
2 of 4
Potential
3 of 4
Risk profile
3 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits far above our value and above the bull case.
BusinessPositive
A solid business that wins patients on price.
GrowthPositive
Patients keep coming and the yearly forecast rose again.
RisksNegative
Medicare may pay less, hospitals may compete on price and the AI plan is unproven.
RivalsMixed
No filed rival compares directly; against its own normal it is far dearer.
The groupMixed
It sits in none of our ranked groups; health reimbursement moves it.
Latest newsMixed
The last report confirmed growth, with too small a margin gain.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.